MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the 'Court') has fully dismissed the application (CV-25-00743454-00CL) (the 'Application') issued by Apollo Technology Capital Corporation ('Apollo') and Nobul Technologies Inc. (together with Apollo, the 'Applicants') against the Company on May 16, 2025 (the 'Notice').
The Applicants sought an order from the Court, amongst other things, appointing a third-party independent chair to preside over the Annual and Special Meeting of Shareholders of the Company (the 'Meeting') on June 16, 2025. The Applicants argued that MediPharm has a 'design or plan to invalidate proxies' and that the Company had acted improperly warranting the appointment of a third-party independent chair.
The Court dismissed the Application in full.
In doing so, the Court found that a third-party independent chair was not required in the circumstances as there was no evidence or indication that MediPharm's proposed meeting chair will act unfairly at the Meeting.
Regarding the conduct of Apollo's principal, Mr. Regan McGee, the Court found:
'The evidence shows that Mr. McGee has threatened to release a draft press release which, among other things, compared Mr. Pidduck to known serial killers. Press Releases have also been issued by Mr. McGee or the Applicants which accuse MediPharm and the Board of securities fraud, breach of fiduciary duty and running a corrupt election process to entrench themselves. Mr. McGee has threatened to sue the Board by way of a derivative action for breach of fiduciary duty and associated damages because of the rejection of the $3.4 million offer and has commenced a lawsuit against MediPharm, two of its senior officers and directors, as well as the Company's external litigation firm (Tyr LLP) and counsel (James Bunting) which claimed $50 million in damages. Mr. McGee, repeated the allegations set out in the lawsuit in the Dissident Circular and then abandoned and withdrew the claim against Tyr LLP and Mr. Bunting, and agreed to terms of settlement that included a declaration by Mr. McGee that Tyr LLP and Mr. Bunting are not in a conflict of interest in acting for MediPharm, that they had not misused confidential information, that Mr. McGee would not disparage Mr. Bunting or Tyr LLP and provided a full release to Tyr LLP and Mr. Bunting.'
The Company remains committed to a fair shareholder meeting process, in compliance with its constating documents and all applicable laws.
We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off.
Vote for the Highly Qualified MediPharm Nominees
MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions.
To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting www.medipharmlabsagm.com.
You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Shareholder Voting Assistance:
If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at:
North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@investor.sodali.comNorth American Toll-Free Facsimile: 1.877.218.5372
For up-to-date information and assistance in voting please visit: www.medipharmlabsagm.com
Investor Contact:
MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@medipharmlabs.com
Media Contact:
John VincicOakstrom Advisors+1 (647) 402-6375john@oakstrom.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, any impacts to MediPharm shareholders of the actions relating to the Applicants or Mr. McGee, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
21 minutes ago
- Hamilton Spectator
Canada could gain as global investors rethink U.S. emphasis: BNP economist
TORONTO - Canada stands to gain as global investors rethink their focus on the United States, the chief economist at one of Europe's largest banks says. BNP Paribas chief economist Isabelle Mateos y Lago said in an interview that the volatility in the U.S. is making investors regain an appreciation of the value of stable returns and predictability, even if it means giving up some of the outsized gains it has offered in recent years. 'The general situation is every investor on the face of the planet has been very overweight (the) U.S. economy, and is now going through a thought process of thinking, maybe I shouldn't be so overweight the U.S. economy, and I need to diversify and find alternatives,' she said. 'So every other geography is going through a bit of a beauty contest right now in the eyes of global investors, and has an opportunity to shine, and I think Canada is one of those.' Mateos y Lago, who was in Toronto this week visiting clients, said Canada's recent election helps give the country some momentum, while efforts to address structural barriers like internal trade will also help growth. 'It's a moment of opportunity and so I would be shocked if Canada didn't benefit from it.' The effects of investors shifting away from the U.S. can already be seen in Canada's main stock index, as the S&P/TSX composite hit record highs this week. Mateos y Lago, who was chief markets strategist at U.S. investment manager BlackRock before taking the top economist job at BNP last year, said the focus on the U.S. in recent years has also meant other markets are relatively cheap, helping make them opportunities worth looking at. European countries are looking to Canada as a source of trade diversification, just as Canada is looking across the Atlantic. Geography does present challenges, but otherwise there's much going for increased ties including language, culture and regulations, she said. 'There are obvious complementarities, and things that should make this easier than with some other potential trade counterparts,' said Mateos y Lago. 'There's a renewed momentum on both sides to try and diversify from the U.S. market, and so this mutual interest, I'm sure the talks will be fruitful.' While Canada already has free trade deals in place with Europe, along with many other partners, Mateos y Lago said there's room to be more ambitious by further reducing tariffs and trade barriers between partners. Prime Minister Mark Carney will have an opportunity to talk directly with his European counterparts as G7 leaders, which include France, Germany, Italy and the United Kingdom along with Japan and the U.S., are set to meet next week in Alberta. As chair of the G7 this year, Canada has an important role to play in trying to save and preserve the rules-based global order that has benefited so many, said Mateos y Lago. 'Canada is one of the countries that can help emphasize the interests that all the key economies have in common, and keep working together and trying to safeguard as much of the existing system of rules as can be because that will be to the benefit of all,' she said. 'The more we see that there is common ground still across all the members of the G7, and maybe on some issues with the broader invited guests, I think the more that will be a sign to economic agents everywhere that it's OK, that the house is still standing.' This report by The Canadian Press was first published June 12, 2025.
Hamilton Spectator
32 minutes ago
- Hamilton Spectator
Descartes Announces Results of Annual Meeting of Shareholders
WATERLOO, Ontario, June 12, 2025 (GLOBE NEWSWIRE) — The Descartes Systems Group Inc. (Nasdaq:DSGX) (TSX:DSG), announced the voting results from its annual meeting of shareholders held on Thursday, June 12, 2025 (the 'Meeting'). Meeting Results The following matters, as set out in more detail in its Management Information Circular dated April 30, 2025, were considered and voted on by shareholders at the Meeting: General The total number of common shares of the Corporation represented in person or by proxy at the Meeting was 77,507,142 which represented 90.35% of the 85,782,830 common shares of the Corporation that were outstanding as of the record date for the Meeting, being April 25, 2025. Election of Directors On a vote by ballot, each of the following 10 nominees proposed by management of the Corporation was elected as a director of the Corporation: Appointment of Auditors On a vote by ballot, KPMG LLP, Chartered Professional Accountants and Licensed Public Accountants, were appointed as the auditors of the Corporation until the close of the next annual meeting of shareholders or until their successors are appointed. Say-On-Pay On a vote by ballot, the 'Say-On-Pay' resolution proposed by management of the Corporation was approved. About Descartes Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, security and sustainability of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, track and help improve the safety, performance and compliance of delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world's largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at , and connect with us on LinkedIn and Twitter . Descartes Investor Contact Laurie McCauley (519) 746-6114 x202358 investor@
Hamilton Spectator
33 minutes ago
- Hamilton Spectator
Draganfly Announces Closing of US$13.75 Million Public Offering
Saskatoon, SK., June 12, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) ('Draganfly' or the 'Company'), a drone solutions, and systems developer, today announced the closing of its previously announced public offering (the 'Offering') of 5,500,000 units, with each unit consisting of one common share and one warrant to purchase one common share. Each unit was sold at a public offering price of US$2.50, for gross proceeds of approximately US$13.75 million, before deducting placement agent discounts and offering expenses. The warrants have an exercise price of CA$5.0768 (or US$3.71) per share, are exercisable immediately and will expire five years following the date of issuance. Maxim Group LLC acted as sole placement agent for the Offering. Draganfly currently intends to use the net proceeds from the Offering for general corporate purposes, including to fund its capabilities to meet demand for its new products including growth initiatives and/or for working capital requirements including the continuing development and marketing of the Company's core products, potential acquisitions and research and development. The Offering was made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No. 333-271498) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission ('SEC') on July 5, 2023 and the Company's Canadian short form base shelf prospectus dated June 30, 2023 (the 'Base Shelf Prospectus'). Draganfly offered and sold the securities in the United States only. No securities were offered or sold to Canadian purchasers. A final prospectus supplement and accompanying Base Shelf Prospectus relating to the Offering and describing the terms thereof has been filed with the applicable securities commissions in the Canadian provinces of British Columbia, Saskatchewan and Ontario, and with the SEC in the United States and is available for free by visiting the Company's profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at or the SEC's website at , as applicable. Copies of the final prospectus supplements and accompanying Base Shelf Prospectus relating to the Offering may be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at syndicate@ . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Draganfly Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) is a pioneer in drone solutions, AI-driven software, and robotics. With over 25 years of innovation, Draganfly has been at the forefront of drone technology, providing solutions for public safety, agriculture, industrial inspections, security, mapping, and surveying. The Company is committed to delivering efficient, reliable, and industry-leading technology that helps organizations save time, money, and lives. Media Contact media@ Company Contact Cameron Chell Chief Executive Officer (306) 955-9907 Email: info@ Forward Looking Statements Certain statements contained in this news release may constitute 'forward-looking statements' or 'forward-looking information' within the meaning of applicable securities laws. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown. In this news release, such forward-looking statements include, but are not limited to, statements regarding the intended use of proceeds of the Offering. Actual future events may differ from the anticipated events expressed in such forward-looking statements. Draganfly believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and Draganfly is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable securities laws. Investors are cautioned not to unduly rely on these forward-looking statements and are encouraged to read the Offering documents, as well as Draganfly's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR+ at and on EDGAR at .
